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Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies
in Acute Coronary Syndrome
Dhruv S. Kazi, MD, MSc, MS; Alan M. Garber, MD, PhD; Rashmee U. Shah, MD, MS; R. Adams Dudley, MD, MBA; Matthew W. Mell, MD;
Ceron Rhee, MBA; Solomon Moshkevich, MBA; Derek B. Boothroyd, PhD; Douglas K. Owens, MD; and Mark A. Hlatky, MD
Background: The choice of antiplatelet therapy after acute coro-
nary syndrome (ACS) is complicated: Ticagrelor and prasugrel are
novel alternatives to clopidogrel, patients with some genotypes may
not respond to clopidogrel, and low-cost generic formulations of
clopidogrel are available.
Objective: To determine the most cost-effective strategy for dual
antiplatelet therapy after percutaneous coronary intervention for
ACS.
Design: Decision-analytic model.
Data Sources: Published literature, Medicare claims, and life tables.
Target Population: Patients having percutaneous coronary inter-
vention for ACS.
Time Horizon: Lifetime.
Perspective: Societal.
Intervention: Five strategies were examined: generic clopidogrel,
prasugrel, ticagrelor, and genotyping for polymorphisms of
CYP2C19 with carriers of loss-of-function alleles receiving either
ticagrelor (genotyping with ticagrelor) or prasugrel (genotyping
with prasugrel) and noncarriers receiving clopidogrel.
Outcome Measures: Direct medical costs, quality-adjusted life-
years (QALYs), and incremental cost-effectiveness ratios (ICERs).
Results of Base-Case Analysis: The clopidogrel strategy produced
$179 301 in costs and 9.428 QALYs. Genotyping with prasugrel
was superior to prasugrel alone, with an ICER of $35 800 per
QALY relative to clopidogrel. Genotyping with ticagrelor was more
effective than genotyping with prasugrel ($30 200 per QALY rela-
tive to clopidogrel). Ticagrelor was the most effective strategy
($52 600 per QALY relative to genotyping with ticagrelor).
Results of Sensitivity Analysis: Stronger associations between
genotype and thrombotic outcomes rendered ticagrelor substan-
tially less cost-effective ($104 800 per QALY). Genotyping with
prasugrel was the preferred therapy among patients who could not
tolerate ticagrelor.
Limitation: No randomized trials have directly compared genotyp-
ing strategies or prasugrel with ticagrelor.
Conclusion: Genotype-guided personalization may improve the
cost-effectiveness of prasugrel and ticagrelor after percutaneous
coronary intervention for ACS, but ticagrelor for all patients may be
an economically reasonable alternative in some settings.
Primary Funding Sources: American Heart Association, U.S. De-
partment of Veterans Affairs, Stanford University, and University of
California San Francisco.
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For author affiliations, see end of text.
Dual antiplatelet therapy combining aspirin with asecond agent is the mainstay of therapy after acute
coronary syndrome (ACS), particularly among patients
who receive a percutaneous coronary intervention (PCI)
(1). Antiplatelet agents reduce thrombotic events, such as
myocardial infarction (MI) and stent thrombosis, but in-
crease risk for bleeding (2). Approximately one half of the
1.1 million ACS events in the United States every year
are treated with a PCI, making the choice of antiplatelet
therapy a common and important clinical decision
(3, 4).
Clopidogrel has been the standard of care after PCI for
nearly a decade (5). Until recently, it was the second-
largest drug in terms of sales, and much of the $12 billion
spent on it each year was for use after ACS (6). However,
many patients receiving clopidogrel and aspirin have recur-
rent cardiovascular events (7, 8), and on-treatment platelet
inhibition varies considerably (9, 10). Patients who carry a
loss-of-function polymorphism of CYP2C19 (a key en-
zyme involved in the hepatic activation of clopidogrel)
achieve less platelet inhibition with clopidogrel and have
more thrombotic events (11–13) and less bleeding. How-
ever, carriers of gain-of-function alleles of the CYP2C19
enzyme achieve greater platelet inhibition with clopidogrel
and have fewer thrombotic events and more bleeding (14,
15).
Two new drugs, prasugrel and ticagrelor, are approved
for use in patients having PCI for ACS (16–19). The
greater antiplatelet activity of these agents reduces the rate
of MI and cardiovascular death compared with clopidogrel.
However, prasugrel increases fatal bleeding so that its net
effect on mortality rates is neutral (16, 17). Ticagrelor is
dosed twice daily and causes mild to moderate dyspnea
in some patients (18, 19), which may adversely affect
adherence. Both agents are expensive, particularly when
compared with generic formulations of clopidogrel that are
now available.
Further, commercial availability of genetic testing may
allow clinicians to personalize antiplatelet therapy so that
See also:
Print
Editorial comment. . . . . . . . . . . . . . . . . . . . . . . . . . 284
Web-Only
Supplement
Annals of Internal Medicine Original Research
© 2014 American College of Physicians 221
Downloaded from https://annals.org by UC Irvine Med Ctr user on 10/04/2019
the new, more expensive drugs could be selectively pre-
scribed to patients most likely to benefit (11, 12, 20, 21).
These recent developments have altered the therapeutic
landscape, highlighting the need for a comprehensive eval-
uation of alternative strategies for dual antiplatelet therapy.
There are no head-to-head clinical trials of ticagrelor with
prasugrel and no prospective studies of genotype-based
treatment decisions. In this article, we present a simulation
that addresses uncertainties about the role of genotyping
and identifies the most cost-effective strategies for dual an-
tiplatelet therapy after PCI for ACS.
METHODS
We developed a discrete-state Markov model to com-
pare 5 strategies of dual antiplatelet therapy (22).
Drug-Only Strategies
Drug-only strategies were generic clopidogrel, prasug-
rel, or ticagrelor. We assumed that generic clopidogrel had
the same efficacy as the proprietary formulation. On the
basis of the results of TRITON-TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel–Thrombolysis in Myo-
cardial Infarction), we assumed that prasugrel led to fewer
cardiovascular deaths but more fatal bleeding compared
with clopidogrel (16, 17). On the basis of the PLATO
(Platelet Inhibition and Patient Outcomes) study, we as-
sumed that ticagrelor reduced cardiovascular deaths with-
out a corresponding increase in fatal bleeding (18, 19) and
that some patients had dyspnea and bradyarrhythmias
while on treatment (23, 24). We did not distinguish be-
tween patients who presented with or without ST-segment
elevations because this feature did not modify the effect of
prasugrel or ticagrelor on the primary end point in either
TRITON-TIMI 38 or PLATO (16, 18).
Genotype-Guided Strategies
We modeled the genotype-guided regimens on the
basis of the recently published guidelines of the Clinical
Pharmacogenetics Implementation Consortium (25) (Ta-
ble 1 of the Supplement, available at www.annals.org).
In the 2 genotype-guided strategies, we assumed that
carriers of 1 or 2 loss-of-function alleles would receive
prasugrel (genotyping-with-prasugrel strategy) or ticagrelor
(genotyping-with-ticagrelor strategy), whereas patients
with 2 gain-of-function alleles, 1 gain-of-function allele
and 1 wild-type allele, or 2 wild-type alleles would be
treated with clopidogrel. Because 1 gain-of-function allele
does not completely compensate for 1 loss-of-function al-
lele (25), such persons would receive prasugrel or ticagrelor
after genotyping. We did not evaluate strategies using tests
of platelet reactivity or clopidogrel dose-escalation because
their clinical relevance was unclear (26, 27).
The base case was a hypothetical cohort of 100 000
patients aged 65 years with ACS who had PCI with 1 or
more drug-eluting stents. All patients received dual anti-
platelet therapy with 1 of the previously mentioned agents
and aspirin for 12 months after the last PCI or MI and
low-dose aspirin daily thereafter unless contraindicated.
We assumed the societal perspective (28), considering all
direct and induced medical costs and relevant clinical out-
comes. Utilities and costs were assigned to each clinical
event in 1-month cycles and discounted at 3% annually
(29). We conducted extensive deterministic, probabilistic,
and scenario-based sensitivity analyses to account for un-
certainty in the input variables. We adhered to the recom-
mendations of the Panel on Cost-Effectiveness in Health
and Medicine (30).
We reported results in 2011 U.S. dollars, quality-
adjusted life-years (QALYs), and incremental cost-
effectiveness ratios (ICERs) (30). For each ICER evalua-
tion, the comparator was the strategy that produced the
next-most QALYs, excluding strategies that cost more
(strictly dominated) or had a greater ICER (dominated by
extension). Because of the inherent challenges of indirect
comparisons between the 2 drugs, we did tiered compari-
sons: We first compared the drug-only strategies (to distin-
guish the drug effect from the effect of genetic testing),
then we examined the effect of genotyping on prasugrel
and ticagrelor separately; finally, we did a global compari-
son across all 5 strategies. Where required, we applied a
willingness-to-pay threshold of $50 000 per QALY.
Modeling was done using TreeAge Pro 2009 (TreeAge
Software, Williamstown, Massachusetts) and Excel 2007
(Microsoft, Redmond, Washington), and statistical analy-
Context
Several options for antiplatelet therapy after percutaneous
coronary intervention for acute coronary syndrome are
available.
Contribution
This cost-effectiveness analysis compared drug-only
strategies (generic clopidogrel, prasugrel, or ticagrelor) and
genotype-guided strategies targeting ticagrelor or prasug-
rel. Ticagrelor was the most cost-effective strategy. The
genotyping-with-prasugrel strategy was superior to giving
all patients prasugrel. The genotyping-with-ticagrelor strat-
egy was clinically superior but more expensive than
clopidogrel.
Caution
No randomized trials have directly compared genotyping
strategies or prasugrel with ticagrelor.
Implication
Genotype-guided personalization of antiplatelet therapy
could improve cost-effectiveness in some situations, but
ticagrelor for all without genotyping also seems
reasonable.
—The Editors
Original Research Antiplatelet Therapy for Acute Coronary Syndrome
222 18 February 2014 Annals of Internal Medicine Volume 160 • Number 4 www.annals.org
Downloaded from https://annals.org by UC Irvine Med Ctr user on 10/04/2019
ses were done using Stata, version 11 (StataCorp, College
Station, Texas).
Model Structure
After the initial PCI, patients were at risk for stent
thrombosis, nonfatal MI (unrelated to stent thrombosis),
percutaneous or surgical revascularization, intracranial and
extracranial bleeding, and death of cardiovascular and non-
cardiovascular causes (Figure 1 of the Supplement). Three
additional states were modeled: Post-MI (patients who had
an MI after entering the model had an increased risk for
future MIs and cardiovascular death); intracranial bleed;
and a “steady state,” into which all patients entered after a
coronary artery bypass graft or 4 years after their initial
PCI, whichever was sooner. The steady state accounted for
age-specific medical costs and QALYs without tracking in-
dividual clinical events.
Model Inputs
Details can be found in the Appendix Table (available
at www.annals.org). For patients in the clopidogrel group,
we estimated the incidence and management of major cor-
onary events from trials (8, 16, 18, 19, 31–37), observa-
tional data (4, 38–54), U.S. life tables (55), U.S. Food and
Drug Administration publications (56), Medicare claims
data (57, 58), clinical guidelines (5, 59–61), and other
publications (48, 62). Event rates in the other groups were
estimated using rate ratios relative to patients on clopi-
dogrel (16–19, 33–35). Long-term survival of patients
with ACS was estimated using Medicare claims data from
2002 to 2006 (Figure 2 of the Supplement) (57, 58). See
the Supplement for additional information.
We estimated the prevalence of loss-of-function poly-
morphisms from published studies (25, 34, 63–65). Al-
though some studies showed that loss-of-function carriers
had a greater rate of thrombotic events than noncarriers
when treated with clopidogrel (66), 2 recent reviews esti-
mated different degrees of association between carrier states
and thrombotic events. In a collaborative, random-effects
model meta-analysis of 9 studies including 9685 patients
(91% of whom had a PCI), Mega and colleagues (12)
found that carriers of 1 or 2 CYP2C19 loss-of-function
alleles had a hazard ratio of 1.57 for thrombotic events
(95% CI, 1.13 to 2.16) relative to noncarriers. In a fixed-
effects model meta-analysis of 42 016 patients from 32
clopidogrel trials that were not limited to patients with
PCI, Holmes and colleagues (67) found that carriers of
loss-of-function alleles had a relative risk of 1.18 (CI, 1.09
to 1.28) for thrombotic events relative to noncarriers. In
light of this uncertainty in the ability of loss-of-function
alleles to discriminate between high- and low-risk patients,
we modeled 2 scenarios (66). In the base-case or low-
discrimination scenario, we modeled conservative correla-
tions as seen by Holmes and colleagues among all patients
treated with clopidogrel, including patients who had not
had PCI (67). In a sensitivity analysis, we modeled a high-
discrimination scenario on the basis of the associations seen
by Mega and colleagues (12) in the cohort of patients
treated with clopidogrel after PCI. In both cases, we as-
sumed that carriers of loss-of-function alleles had a lower
risk for bleeding than noncarriers (67).
Carriers of gain-of-function alleles achieved a greater
degree of platelet inhibition than patients with wild-type
alleles treated with clopidogrel, which translated into fewer
thrombotic events and increased bleeding (14, 15). Be-
cause some evaluations suggested that this correlation
may be partly due to linkage disequilibrium with loss-of-
function alleles, we conducted a sensitivity analysis that
assumed no correlation between gain-of-function alleles
and outcomes (25). We assumed that genotyping was
100% sensitive and 99.3% specific in detecting CYP2C19
alleles (21) but varied these assumptions in sensitivity anal-
yses. The pharmacologic effects of ticagrelor and prasugrel
are unaffected by genotype (34, 35, 68, 69), so the model
assumed that carriers and noncarriers have similar out-
comes when treated with 1 of these drugs.
Quality-of-Life Estimates
We estimated age-specific quality of life (70), which
we also adjusted for adverse clinical events or invasive pro-
cedures (71–76). We assumed that patients who had an MI
or stent thrombosis had a 12% permanent quality-of-life
decrement relative to their age-matched counterparts (77),
patients who had a nonfatal intracranial hemorrhage had a
61% permanent quality-of-life decrement (78), and pa-
tients with ticagrelor-associated dyspnea had a quality-of-
life decrement equal to that of patients with a history of
angina (79).
Costs
We included direct medical costs (such as inpatient
admissions, procedures, outpatient visits, and drugs) and
induced costs (such as cost of procedural complications)
but not indirect costs (such as lost wages and caregiver
costs). We estimated acute event costs from Medicare re-
imbursement rates, the Nationwide Inpatient Sample, and
the published literature (74, 80–82). We estimated age-
specific costs of outpatient and total medical care from the
Agency for Healthcare Research and Quality’s Medical Ex-
penditure Panel Survey (83). All costs were converted to
2011 dollars using the U.S. gross domestic product defla-
tor (84).
We assumed a base-case cost of $30 per month for
generic clopidogrel and included the current average
wholesale price of the proprietary formulation ($218 per
month) in the sensitivity analyses (82). We assumed the
costs of prasugrel and ticagrelor to equal their average
wholesale price ($220 and $261 per month for prasugrel
and ticagrelor, respectively) (82). We estimated the cost of
genotyping from a survey of retail prices of commercially
available tests but included the estimated unit cost of
point-of-care tests in the range tested in sensitivity analyses.
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Role of the Funding Source
This study was funded by the American Heart Associ-
ation, U.S. Department of Veterans Affairs, Stanford Uni-
versity, and the University of California San Francisco.
The funding source had no role in the design, conduct, or
interpretation of the study or the preparation, review, or
approval of the manuscript.
RESULTS
The estimated model outcomes compared well with
the experience of Medicare enrollees from 2002 to 2005.
Mortality rates in the clopidogrel group of the model were
similar to the mortality rates among 65-year old Medicare
patients at 1 year (4.6% vs. 4.6%) and 5 years (17.3% vs.
17.4%). Patients aged 65 years having PCI for ACS who
were treated with 12 months of clopidogrel and aspirin
were projected to have a life expectancy of 11.4 life-years
(15.2 undiscounted life-years), with $179 301 in costs and
9.428 QALYs over their lifetimes (Table 1).
Clinical Events and Cost-Effectiveness
Drug-Only Strategies
Both prasugrel and ticagrelor reduced thrombotic
events relative to clopidogrel, but patients receiving prasu-
grel had substantially greater fatal bleeding (Table 2 of
the Supplement). As a result, prasugrel was relatively ex-
pensive, with an ICER of $124 400 per QALY relative to
clopidogrel, whereas ticagrelor had a lower ICER of
$22 800 per QALY relative to prasugrel. Thus, prasugrel
was eliminated by extended dominance, and ticagrelor had
an ICER of $40 300 per QALY relative to clopidogrel.
All Strategies
In the base case, we assumed that loss-of-function al-
leles were only modestly correlated with thrombotic out-
Table 1. Incremental Cost-Effectiveness of Strategies for Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for
Acute Coronary Syndrome*
Strategy Costs, $ Outcomes Incremental
Costs, $
Incremental
QALYs, n
ICER,
$/QALY†
Study
Drug and
Genotyping
Total Cardiovascular
Death, %‡
Fatal
Bleed, %‡
Life
Years, n
QALYs, n
Drug-only therapy
Generic clopidogrel 366 179 301 9.87 0.45 11.41 9.428 – – –
Prasugrel 2687 181 546 9.38 0.95 11.43 9.446 2244 0.018 Dominated§
Ticagrelor 2978 183 531 9.15 0.43 11.54 9.533 4230§ 0.105§ 40 270§
Low-discrimination scenario
Generic clopidogrel 366 179 301 9.87 0.45 11.41 9.428 – – –
Prasugrel 2687 181 546 9.38 0.95 11.43 9.446 2244 0.018 Dominated
Genotyping with prasugrel¶ 1269 180 470 9.49 0.61 11.45 9.461 1169 0.033 Dominated**
Genotyping with ticagrelor†† 1352 181 040 9.44 0.45 11.48 9.486 1739** 0.058** 30 200**
Ticagrelor 2978 183 531 9.15 0.43 11.54 9.533 2491 0.047 52 600
High-discrimination scenario
Generic clopidogrel 366 179 301 9.87 0.45 11.41 9.429 – – –
Prasugrel 2687 181 546 9.38 0.95 11.43 9.446 2244 0.018 Dominated††
Genotyping with prasugrel¶ 1269 180 819 9.22 0.62 11.48 9.488 1518†† 0.059†† Dominated‡‡
Genotyping with ticagrelor§§ 1353 181 390 9.17 0.45 11.51 9.513 2089‡‡ 0.084‡‡ 24 700‡‡
Ticagrelor 2978 183 531 9.15 0.43 11.54 9.533 2141 0.020 104 800
ICER  incremental cost-effectiveness ratio; QALY  quality-adjusted life year.
* Costs are expressed in 2011 U.S. dollars. Costs, QALYs, and life expectancy are discounted at 3% a year.
† Incremental cost-effectiveness for each strategy was measured relative to the next-best strategy that had not been eliminated by dominance and was rounded to the closest
$100 to reflect the precision in the model.
‡ Proportion of patients who die of a cardiovascular cause or fatal bleed in the first 4 y after index percutaneous coronary intervention.
§ The ICER of prasugrel relative to clopidogrel ($124 400/QALY) was greater than the ICER of ticagrelor, relative to prasugrel ($22 800/QALY). Prasugrel was therefore
eliminated from the comparison by the principle of extended dominance, and ticagrelor was compared directly with clopidogrel.
 In the genotyping with prasugrel strategy, carriers of 1 or 2 loss-of-function polymorphisms in CYP2C19 were treated with prasugrel; the others received generic clopidogrel.
¶ In the low-discrimination scenario, prasugrel cost $1076 more than the genotyping-with-prasugrel strategy and produced 0.015 fewer QALYs. It was therefore eliminated
from the evaluation (strictly dominated), and genotyping with prasugrel was compared with clopidogrel.
** In the low-discrimination scenario, the ICER of genotyping with prasugrel relative to clopidogrel ($35 800/QALY) was less favorable than the ICER of genotyping with
ticagrelor relative to genotyping with prasugrel ($22 800/QALY). Therefore, genotyping with prasugrel was eliminated from the comparison by the principle of extended
dominance, and genotyping with ticagrelor was compared directly with clopidogrel.
†† In the high-discrimination scenario, prasugrel cost $727 more than genotyping with prasugrel and produced 0.042 fewer QALYs. Prasugrel was therefore eliminated from
the evaluation (strictly dominated), and genotyping with prasugrel was compared with clopidogrel.
‡‡ In the high-discrimination scenario, the ICER of genotyping with prasugrel relative to clopidogrel ($25 600/QALY) was less favorable than the ICER of genotyping with
ticagrelor relative to genotyping with prasugrel ($22 800/QALY). Therefore, genotyping with prasugrel was eliminated from the comparison by the principle of extended
dominance, and genotyping with ticagrelor was compared directly with clopidogrel.
§§ In the genotyping-with-ticagrelor strategy, carriers of 1 or 2 loss-of-function polymorphisms in CYP2C19 were treated with ticagrelor; the others received generic
clopidogrel.
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comes (12). When all 5 strategies were considered in order
of increasing QALYs gained and compared incrementally
(Table 1 and Figure 1), the prasugrel strategy was more
expensive and had worse outcomes than genotyping with
prasugrel and was therefore eliminated (“dominated”).
Next, the ICER for genotyping with prasugrel relative to
clopidogrel ($35 800 per QALY) was less favorable than
the ICER for genotyping with ticagrelor relative to geno-
typing with prasugrel ($22 800 per QALY); genotyping
with prasugrel was therefore inside the “cost-effectiveness
frontier” and was eliminated (Figure 1). Genotyping with
ticagrelor was therefore compared directly with clopidogrel
(the next-best, nondominated strategy) and yielded an
ICER of $30 200 per QALY. The ticagrelor-for-all strategy
produced the highest QALYs but was also the most expen-
sive with a less favorable ICER ($52 600 per QALY rela-
tive to genotyping with ticagrelor).
Sensitivity Analyses
High-Discrimination Scenario
Assuming stronger associations between loss-of-
function genotype and thrombotic outcomes greatly in-
creased the cost-effectiveness of genotyping-based strategies
(Table 1 and Figure 1) (12). In this setting, genotyping
with ticagrelor was the most cost-effective strategy, with an
ICER of $24 700 per QALY. Treating all patients with
ticagrelor produced 0.02 additional QALYs but was eco-
nomically unattractive, with an ICER of $104 800 per
QALY relative to genotyping with ticagrelor.
Efficacy and Safety Variables
The cost-effectiveness of genotyping with ticagrelor
was sensitive to modest changes in assumptions about the
efficacy and safety of ticagrelor relative to clopidogrel and
the association between thrombotic events in loss-of-
function carriers relative to noncarriers (Table 3 of the
Supplement and Appendix Figures 1 and 2, available at
www.annals.org). For instance, if the rate of cardiovascular
death among patients treated on ticagrelor decreased by
1.3% or the rate of fatal bleeding by 38.0%, treating all
patients with ticagrelor became the most cost-effective
strategy. In contrast, in the high-discrimination scenario,
the optimal strategy—genotyping with ticagrelor—was ro-
bust to wide variations in underlying assumptions (Table 3
of the Supplement).
Ticagrelor-Associated Dyspnea
The choice of optimal therapy was sensitive to the
decrement in the patient’s quality of life from ticagrelor-
associated dyspnea (Figure 3 of the Supplement). A utility
decrement of greater than 0.049 (6% of baseline quality
of life at the age of 65 years) made genotyping with prasu-
grel the most cost-effective therapy.
Figure 1. Cost-effectiveness plane.
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Results of the base-case analysis are presented on the cost-effectiveness plane, with clopidogrel at the origin. The lines indicate the cost-effectiveness
frontier, and the slope of the frontier that connects 2 strategies is the incremental cost-effectiveness ratio (in 2011 U.S. dollars per QALY). Both low-
(solid line) and high-discrimination scenarios (dashed line) are shown; strategies that are inside the corresponding frontier (hollow markers) are eliminated
by strict or extended dominance.
Original ResearchAntiplatelet Therapy for Acute Coronary Syndrome
www.annals.org 18 February 2014 Annals of Internal Medicine Volume 160 • Number 4 225
Downloaded from https://annals.org by UC Irvine Med Ctr user on 10/04/2019
Allelic Frequency
The population frequency of loss-of-function alleles
varied substantially by race and ethnicity, and it was con-
siderably greater in South Asia (35%), East Asia (40%),
and Oceania (76%) than in Europe (16%) or Africa (16%)
(25). As the proportion of carriers 1 or 2 loss-of-function
alleles increased, both genotyping with ticagrelor and ti-
cagrelor became increasingly cost-effective (Appendix Fig-
ure 3, available at www.annals.org). Treating all patients
with ticagrelor was the most cost-effective therapy when
loss-of-function carriers constituted more than 52.7% of
the population. In contrast, increasing population fre-
quency of the gain-of-function allele did not materially
affect the cost-effectiveness of genotyping but made the
ticagrelor-for-all strategy less cost-effective (Figure 4 of the
Supplement).
Accuracy of Genetic Testing
The ICER for ticagrelor relative to genotyping with
ticagrelor was affected by the accuracy of genotyping (Fig-
ure 5 of the Supplement), and declining accuracy favored
treating all patients with ticagrelor independent of geno-
type. For instance, if the sensitivity and specificity of the
test were 95% (instead of the base case of 100% sensitivity
and 99.3% specificity), the ICER for ticagrelor would de-
crease to $51 500 per QALY and the ICER for genotyping
with ticagrelor would increase to $31 500 per QALY.
Cost of Genetic Testing
In the low-discrimination scenario, it was cost-
effective to treat all patients with ticagrelor regardless of
genotype if genetic testing cost more than $358 per patient
(Figure 6 of the Supplement). In the high-discrimination
scenario, genotyping with ticagrelor was the most cost-
effective strategy until the cost of genetic testing exceeded
$1355.
Drug Costs
The choice of optimal antiplatelet therapy was sensi-
tive to the difference in the monthly cost of ticagrelor and
clopidogrel: Smaller differences in cost made both ticagre-
lor and genotyping with ticagrelor more cost-effective (Fig-
ure 7 of the Supplement). In the low-discrimination sce-
nario, treating all patients with ticagrelor was the most
cost-effective strategy when the difference in monthly cost
of ticagrelor and clopidogrel decreased from a base case of
$231 to $215, either because ticagrelor was less expensive
or clopidogrel was more expensive than the base case. In
the high-discrimination scenario, the difference had to de-
crease to $93 or less to make ticagrelor cost-effective at a
threshold of $50 000 per QALY.
Duration of Dual Antiplatelet Therapy
The absolute cardiovascular risk was greatest in the
first year after PCI, whereas bleeding risk and drug costs
persisted for the entire duration of antiplatelet therapy.
Therefore, dual antiplatelet therapy became less economi-
cally attractive as the duration of treatment increased from
12 to 36 months. The genotyping-with-ticagrelor strategy
remained the most cost-effective alternative for dual anti-
platelet therapy after PCI for ACS, with an ICER less than
$50 000 per QALY (Figure 8 of the Supplement).
Probabilistic Sensitivity Analysis
We performed 10 000 microsimulations where all in-
put variables were varied simultaneously along prespecified
distributions. In the low-discrimination scenario, genotyp-
ing with ticagrelor was the preferred strategy in 39% of the
simulations and ticagrelor in 42% of the simulations (Fig-
ure 2). In the high-discrimination scenario, the preferred
strategy was genotyping with ticagrelor in 63% of the sim-
ulations, ticagrelor in 19%, and genotyping with prasugrel
in 13% (Figure 2). Ticagrelor was the preferred strategy in
more than 50% of simulations at thresholds greater than
$54 500 per QALY in the low-discrimination scenario and
$98 000 per QALY in the high-discrimination scenario.
Scenario Analyses
The optimal strategies for dual antiplatelet therapy un-
der different clinical scenarios in which ticagrelor or prasu-
grel may not be indicated (for example, among patients
with a history of a transient ischemic attack) are presented
in Table 2. Additional sensitivity analyses are presented in
Tables 4 to 7 and Figures 9 to 13 of the Supplement.
DISCUSSION
Nearly 500 000 patients in the United States face the
choice of dual antiplatelet therapy after PCI for ACS every
year. This choice has substantial clinical and economic im-
plications and entails a marked difference in drug costs as
well as a tradeoff between thrombotic events and major
bleeding. Our analysis suggests that genotype-guided per-
sonalization of therapy may improve the cost-effectiveness
of the newer, more expensive antiplatelet agents. The tar-
geted use of prasugrel in carriers of CYP2C19 loss-of-
function alleles consistently decreased costs and improved
outcomes relative to treating all patients with prasugrel,
making genotyping before treatment with prasugrel the
clinically and economically superior strategy. The selective
use of ticagrelor in CYP2C19 loss-of-function carriers and
clopidogrel in noncarriers was the most cost-effective strat-
egy when genotyping discriminates well between patients
at high and low risk for thrombotic events (that is, where
there is a strong association between genotype and clinical
outcomes). If genotype were only modestly predictive of
thrombotic outcomes, ticagrelor for all patients indepen-
dent of genotype would be the most cost-effective strategy
for dual antiplatelet therapy after PCI for ACS.
Genotype-guided therapy aims to reduce costs and im-
prove outcomes by targeting the use of the more expensive
Original Research Antiplatelet Therapy for Acute Coronary Syndrome
226 18 February 2014 Annals of Internal Medicine Volume 160 • Number 4 www.annals.org
Downloaded from https://annals.org by UC Irvine Med Ctr user on 10/04/2019
drugs to patients most likely to benefit from them. Con-
trary to concerns that cost-effectiveness considerations en-
courage a “1-size-fits-all” approach (85) or “stymie progress
in personalized medicine” (86), models such as ours that
estimate clinically meaningful outcomes among genetic
subgroups of patients can help clarify the potential value of
individualized therapeutics (87). Further, sensitivity analy-
ses help quantify the effect of uncertainty on clinical and
policy-level decision making and identify the knowledge
gaps that should be addressed in future research. Our study
highlights that a well-designed cost-effectiveness analysis
can both support and guide innovation in personalized
medicine (87).
Our results suggest 4 key considerations in the choice
of antiplatelet therapy after PCI for ACS. First, clinicians
should consider genotyping all patients before using prasu-
grel because targeted use of prasugrel therapy among loss-
of-function carriers seems to reduce costs and improve
clinical outcomes. Second, clinicians should be cognizant
of the effect of ticagrelor-associated dyspnea on the pa-
Figure 2. Probabilistic sensitivity analysis.
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Results of the probabilistic sensitivity analysis are illustrated as acceptability curves, which plot the proportion of simulations in which a certain strategy
is “optimal” (or most cost-effective) against the amount one is willing to pay per QALY gained. In the low-discrimination scenario, genotyping with
ticagrelor is the preferred strategy in 42.3% of the simulations at a willingness-to-pay threshold of $50 000/QALY (green vertical line) and ticagrelor is
the preferred strategy in 32% of the simulations, reflecting the underlying uncertainty. Greater thresholds make ticagrelor more economically attractive.
In the high-discrimination scenario, which assumes stronger associations between loss-of-function genotype and the rate of thrombotic events, genotyping
with ticagrelor is the optimal strategy in 63.4% of the simulations at a threshold of $50 000/QALY. QALY  quality-adjusted life-year.
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tient’s quality of life. Among patients with a moderate to
severe decrement in quality of life due to ticagrelor-
associated dyspnea (6% reduction in on-treatment qual-
ity of life relative to baseline), genotyping with prasugrel is
the most cost-effective strategy (that is, loss-of-function
carriers should receive prasugrel, and noncarriers should
receive clopidogrel). Third, genotype-guided antiplatelet
therapy may be less attractive in populations or regions
with a high prevalence of loss-of-function alleles, where
treating all patients with ticagrelor may be the most cost-
effective strategy. Future research should specifically exam-
ine the role of genotyping among patients with ancestry in
South and East Asia and Oceania, in whom the population
frequency of loss-of-function alleles is considerably greater
than among patients with European, American, or African
ancestry (25). Fourth, genotyping may be less economically
attractive in health care markets where the monthly cost of
ticagrelor is closer to the monthly cost of generic clopi-
dogrel because the cost-effectiveness of genotyping is sen-
sitive to cost differences between the drugs. Treating all
patients with ticagrelor independent of genotype becomes
the most cost-effective strategy when the difference in
monthly cost of ticagrelor and clopidogrel is less than
$215.
There are several limitations to this study. Estimated
differences in outcomes between various CYP2C19
genotypes are largely based on post hoc analyses of ran-
domized trials. Systematic reviews of the literature have
yielded variable results depending upon studies included,
definition of end points, and statistical models used. We
address this uncertainty by presenting both a low-
discrimination scenario that assumes a modest ability to
discriminate between high- and low-risk patients on the
basis of genotype, as well as a high-discrimination scenario,
which assumes a stronger association between genotype
and thrombotic outcomes. Future randomized trials of
genotype-tailored strategies, either alone or in combination
with phenotype-based strategies (for example, based on the
measurement of on-treatment platelet reactivity), should
help further clarify the role of personalization in optimiz-
ing antiplatelet therapy after PCI (88).
Estimates of the efficacy and safety of prasugrel and
ticagrelor are based on only 1 large, randomized, clinical
trial of each drug versus clopidogrel (16, 18). The indirect
comparison of ticagrelor with prasugrel inherent in the
structure of the model is limited by structural differences in
the design and execution of the PLATO and TRITON-
TIMI 38 clinical trials, as well as any clinical differences in
the patients enrolled in these trials. Although a definitive,
large, randomized, clinical trial comparing various strate-
gies for dual antiplatelet therapy among real-world patients
would be ideal, the prohibitive logistics of such a trial argue
for comparative effectiveness studies of ticagrelor and pra-
sugrel on the basis of a large, observational study or prag-
matic clinical trial. Until either is done, models such as
ours that incorporate a wide range of sensitivity analyses
facilitate a systematic synthesis of published data. To alle-
viate confounding arising from interstudy variations, we
used data from previously published trials and observa-
tional analyses to model baseline event rates in the clopi-
dogrel group and used rate ratios from TRITON-TIMI 38
and PLATO to model event rates among patients on pra-
sugrel and ticagrelor, respectively.
A post hoc analysis of patients receiving prasugrel in
TRITON-TIMI 38 (16) found an increase in bleeding
among patients with a history of stroke or transient
ischemic attack; prasugrel is contraindicated in this sub-
group. It is possible that prasugrel compares more favor-
ably with clopidogrel in patients without a history of stroke
or transient ischemic attack than indicated by the full-trial
estimates used in this model. A subgroup analysis of pa-
tients receiving ticagrelor in PLATO found that patients
recruited in North America had worse outcomes than pa-
tients from other geographic regions. This may represent a
chance finding, a dose-dependent interaction with aspirin,
or a real discrepancy arising from international differences
in treatment algorithms (89). In line with the U.S. Food
and Drug Administration approval of the drug, we as-
Table 2. Optimal Strategy for Dual Antiplatelet Therapy
Under Different Clinical Scenarios
Scenario Most Effective
Therapy
Most
Cost-Effective
Therapy*
Patient unable to tolerate
ticagrelor†
Generic clopidogrel
available
Genotyping with
prasugrel‡
Genotyping with
prasugrel
No clopidogrel generics Genotyping with
prasugrel
Genotyping with
prasugrel
Genotyping unavailable Prasugrel Clopidogrel
Patient with a history of
TIA or stroke
Clopidogrel Clopidogrel
Patient with a history of TIA
or ischemic stroke§
Generic clopidogrel
available
Ticagrelor Genotyping with
ticagrelor
No clopidogrel generics Ticagrelor Ticagrelor
Genotyping unavailable Ticagrelor Ticagrelor
Ticagrelor not tolerated Clopidogrel Clopidogrel
TIA  transient ischemic attack.
* Cost-effectiveness threshold was $50 000 per quality-adjusted life year.
† Ticagrelor is contraindicated in patients with a history of hemorrhagic stroke. In
a small group of patients, ticagrelor produces a syndrome of subjective dyspnea
that may last several months. In some patients, this may be severe enough to result
in discontinuation of the medication.
‡ In the genotyping-with-prasugrel strategy, patients with 1 or 2 loss-of-function
polymorphisms in CYP2C19 were treated with prasugrel; the others received
clopidogrel.
§ Prasugrel is contraindicated in patients with a history of stroke or transient
ischemic attack. Caution is also advised for patients weighing less than 60 kg and
those who are aged 75 y.
 In the genotyping-with-ticagrelor strategy, patients with 1 or 2 loss-of-function
polymorphisms in CYP2C19 were treated with ticagrelor; the others received
clopidogrel. If a threshold of $50 000 per quality-adjusted life-year was assumed,
then ticagrelor was the most cost-effective therapy if the monthly price difference
between ticagrelor and clopidogrel was less than $215/mo (low-discrimination
scenario) or $93/mo (high-discrimination scenario).
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sumed that the clinical outcomes seen in PLATO can be
achieved in U.S. patients on low-dose aspirin therapy, but
this will need to be confirmed in future studies. Short-term
clinical trials may not adequately define all potential safety
concerns with a drug (23, 90, 91). Pursuant to the “life-
cycle approach” to drug safety recommended by the Insti-
tute of Medicine (92), our analysis should be updated
when safety and efficacy data from phase 4 trials or regis-
tries become available.
Our results are broadly concordant with previously
published analyses that have found genotyping-based per-
sonalization of antiplatelet therapy to be cost-effective in
other health systems (93, 94) but are more conservative
than those reported by the trialists themselves (95–98). For
instance, the investigators of TRITON-TIMI 38 con-
cluded that treating patients with prasugrel after PCI for
ACS was cost-effective at $50 000 per life-year gained,
largely because of a substantially greater gain in life expec-
tancy with prasugrel treatment in their model than seen in
our analysis (96). This is probably the result of key meth-
odological differences between the 2 studies—for instance,
the trialists estimated life expectancy from a data set of
patients who underwent angioplasty in Saskatchewan,
Canada, between 1985 and 1995 (before the widespread
adoption of intracoronary stenting) (96), whereas we based
our estimate on U.S. Medicare beneficiaries who had a PCI
for ACS between 2002 and 2005. Nevertheless, the results
of our sensitivity analyses underscore the need to accurately
define the long-term effect of newer antiplatelet agents on
mortality rates, which would define their relative cost-
effectiveness in the real world.
Based on currently available evidence, genotyping pa-
tients having PCI for ACS, followed by the targeted use of
ticagrelor in carriers of loss-of-function CYP2C19 alleles
and clopidogrel in noncarriers is economically attractive
compared with treating all patients with the newer agents
or clopidogrel. However, ticagrelor for all patients inde-
pendent of genotype may be an economically reasonable
alternative in some populations and settings. Future studies
should directly compare prasugrel with ticagrelor, assess
the effect of ticagrelor-associated dyspnea on quality of life,
and prospectively establish the role of personalization of
antiplatelet therapy after PCI for ACS.
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Appendix Table. Summary of Key Model Variables
Variable Point Estimate Range Reference
Baseline events*
Stent thrombosis while receiving clopidogrel and aspirin 38–46, 72
Rate per person of early (days 1–30) stent thrombosis 0.0150 0.010–0.020
Rate per person of late (days 31–365) stent thrombosis 0.0060 0.003–0.009
Annual rate per person of very late (beyond 365 d) stent thrombosis 0.0022 0.001–0.003
Duration of very late stent thrombosis, y 4 2–5 72
Case fatality from stent thrombosis, % 20 15–30 72
Annual rate per person of bleeds while receiving clopidogrel and aspirin
Non–CABG-related bleeding 8, 16, 18, 31, 50
Extracranial (TIMI major and nonfatal) 0.0230 0.015–0.070
Intracranial (TIMI major and nonfatal) 0.0015 0.001–0.002
TIMI minor 0.0200 0.010–0.060
Fatal 0.0015 0.001–0.003
CABG-related TIMI major bleeding 0.0220 0.013–0.031 8, 32
Annual rate per person for nonfatal MI, on clopidogrel and aspirin, excluding
definite and probable stent thrombosis
0.0350 0.013–0.097 16–19, 57, 58, 62, 72
Management of each episode of nonfatal MI, % 4, 72
PCI 55 45–65
CABG 08 04–12
Medical management 37 23–51
Annual rate per person of nonurgent revascularization
Year 1 after initial PCI for ACS 0.10 0.05–0.15 57, 58
Beyond year 1 after initial PCI for ACS 0.03 0.02–0.04 57, 58
Surgical revascularization (CABG vs. PCI), % 25 15–35 4, 49, 57, 58
Rate per person of all-cause mortality after initial PCI Age-specific 55, 57, 58
Deaths due to cardiovascular causes, year 1 after PCI for ACS, % 80 72–88 8, 16, 18
Deaths due to cardiovascular causes, beyond year 1 after PCI for ACS, % 67 60–73 51
Procedural complications, %
Periprocedural death due to PCI 0.12 0.10–1.00 72
Periprocedural death due to CABG 2.10 1.00–10.00 72
Rate ratios†
Cardiovascular mortality, relative to clopidogrel and aspirin
Aspirin monotherapy 1.08 0.94–1.24 8
Ticagrelor and aspirin 0.79 0.69–0.91 18, 19
Prasugrel and aspirin 0.89 0.70–1.12 16, 17
Noncardiovascular, unrelated to bleeding, relative to clopidogrel and aspirin
Aspirin monotherapy 1.00 0.90–1.10 Assumed
Ticagrelor and aspirin 0.63 0.39–1.03 18, 19
Prasugrel and aspirin 0.81 0.51–1.27 16, 17
Nonfatal MI, relative to clopidogrel and aspirin
Aspirin monotherapy 1.29 1.12–1.48 8
Ticagrelor and aspirin 0.84 0.75–0.95 18, 19
Prasugrel and aspirin 0.76 0.67–0.85 16, 17
Stent thrombosis, relative to clopidogrel and aspirin
Aspirin monotherapy 1.29 1.12–1.48 8
Ticagrelor and aspirin 0.75 0.59–0.95 18, 19
Prasugrel and aspirin 0.48 0.36–0.64 16, 17
Nonfatal extracranial TIMI major bleeds, relative to clopidogrel and aspirin
Aspirin monotherapy 0.72 0.60–1.00 8, 31, 62
Ticagrelor and aspirin 1.30 1.05–1.61 18, 19
Prasugrel and aspirin 1.22 0.93–1.6 16, 17
Nonfatal intracranial TIMI major bleeds, relative to clopidogrel and aspirin
Aspirin monotherapy 0.71 0.23–2.23 8, 31, 62
Ticagrelor and aspirin 1.15 0.55–2.41 18, 19
Prasugrel and aspirin 0.83 0.36–1.92 16, 17
Nonfatal extracranial TIMI minor bleeds, relative to clopidogrel and aspirin
Aspirin monotherapy 0.47 0.39–0.57 8, 31, 62
Ticagrelor and aspirin 1.07 0.91–1.26 18, 19
Prasugrel and aspirin 1.16 0.91–1.49 16, 17
Fatal bleeds, relative to clopidogrel and aspirin
Aspirin monotherapy 1.35 0.62–2.95 8, 31, 62
Ticagrelor and aspirin 0.87 0.48–1.59 18, 19
Prasugrel and aspirin 4.19 1.58–11.11 16, 17
CABG-related TIMI major bleeds, relative to clopidogrel and aspirin
Aspirin monotherapy 1.08 0.61–1.91 8, 31, 32
Ticagrelor and aspirin 1.08 0.85–1.36 33
Prasugrel and aspirin 4.73 1.90–11.82 16, 17
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Appendix Table—Continued
Variable Point Estimate Range Reference
Genetic testing
Clinical events among carriers of loss-of-function alleles treated with
clopidogrel, relative to noncarriers treated with clopidogrel
Stent thrombosis
Low-discrimination scenario 1.75 1.50–2.03 67
High-discrimination scenario 2.81 1.81–4.37 12
MI
Low-discrimination scenario 1.48 1.05–2.07 67
High-discrimination scenario 1.45 1.09–1.92 12
Mortality
All-cause, low-discrimination scenario‡ 1.28 0.95–1.73 67
Cardiovascular, high-discrimination scenario 1.84 1.03–3.28 12
Bleeding 0.84 0.75–1.00 11, 34, 67, 69
Clinical events among carriers of gain-of-function alleles treated with
clopidogrel, relative to patients with wild-type alleles treated with
clopidogrel
Thrombotic events 0.75 0.66–1.00 14, 15
Bleeding 1.26 1.00–1.50 14, 15
Other key transition probabilities
Duration of dual antiplatelet therapy, time since last PCI or ACS, whichever
is later, mo
12 12–48 5, 59–61
Duration of aspirin monotherapy after completion of dual antiplatelet
therapy, mo
For life – 5, 59–61
Genotype composition of the cohort, % 25, 34, 63–65
Carriers of 1 or 2 loss-of-function and no gain-of-function alleles 21 0.15–0.40
Carriers of 1 or 2 gain-of-function and no loss-of-function alleles 33 0.10–0.40
Carriers of 1 gain-of-function and 1 loss-of-function allele 7 0.05–0.09
Accuracy of genetic testing, %
Sensitivity 100 95–100 21
Specificity 99.3 95–100 21
Quality-of-life estimates (utilities)
Baseline values Age-specific – 70
Disutility tolls
Bleeding 62, 63, 72–75
Intracranial 0.61 0.4–0.8
Extracranial 0.2 for 14 d 7–21 d
Minor 0.2 for 2 d 0–7 d
CABG-related bleed 0.5 for 7 d 3–14 d
Revascularization 72,75
CABG 0.5 for 14 d 7–21 d
PCI 0.5 for 7 d 3–14 d
Nonfatal MI 0.13 for 1 m, then 0.12 0.05–0.25, then 0.07–0.16 70, 72, 75, 77
Ticagrelor-related dyspnea 79
Mild 0.071 0.018–0.124
Moderate 0.102 0.043–0.161
Severe 0.338 0.150–0.526
Syncope or bradyarrhythmia 0.24 for 3 d 1–7 d 76
Costs, $§
Monthly medical costs
Clopidogrel 30 4–200 82
Prasugrel 220 150–300 82
Ticagrelor 261 150–300 82
Aspirin 4 2–10 Assumed
Costs of acute care
Nonfatal extracranial hemorrhage 10 120 5060–20 240 80, 84
Nonfatal intracranial hemorrhage 20 740 10 370–41 480 80, 84
TIMI minor bleed 79 40–158 81, 84
Fatal bleed 17 920 8960–35 840 80, 84
CABG-related bleed 35 570 17 790–71 140 80, 84
Fatal MI 24 540 12 270–49 080 80, 84
Nonfatal MI, PCI 27 840 13 920–55 680 80, 84
Nonfatal MI, medical management 17 200 8600–34 400 80, 84
Hospitalization for syncope 11 467 5734–22 934 80, 84
Admission to observation unit 4877 2439–9754 80, 84
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Appendix Table—Continued
Variable Point Estimate Range Reference
Inpatient cardiovascular death 27 630 13 820–55 260 80, 84
Inpatient noncardiovascular death 24 630 12 320–49 260 80, 84
CYP2C19 genetic test 235 100–700 Market research
Revascularization
Elective PCI 20 670 10 340–41 340 80, 84
Elective CABG 50 560 25 280–101 120 80, 84
CABG after MI 67 720 33 860–135 440 80, 84
Annual discount rate, % 3 0–5 29
ACS  acute coronary syndrome; CABG  coronary artery bypass graft; MI  myocardial infarction; PCI  percutaneous coronary intervention; TIMI  thrombolysis
in myocardial infarction.
* Rates are per person-year unless otherwise specified.
† Hazard ratios and CIs were used if reported; if they were not reported, point estimate and CI for rate ratios were estimated from reported events.
‡ In the low-discrimination scenario, the rate of cardiovascular mortality among patients treated with clopidogrel was estimated within the model on the basis of all-cause
mortality and the proportion of all deaths attributable to cardiovascular causes.
§ In 2011 U.S. dollars.
Appendix Figure 1. Sensitivity analysis on the association
between genotype and clinical outcomes.
IC
ER
, $
/Q
A
LY
Change in Rate of Thrombotic Events
Among Carriers of Loss-of-Function Alleles Relative to Noncarriers
Declining
 Discrimination
Improving
Discrimination
Genotyping with 
ticagrelor
Ticagrelor
–20% Base Case +20% +40% +60%
0
50 000
100 000
150 000
200 000
250 000
The value of genotyping depends on its ability to discriminate between
patients at high and low risk for thrombotic events. In this analysis, the
base case assumes a low-discrimination scenario: that carriers of loss-of-
function alleles are at modestly greater risk for thrombotic events than
noncarriers. The ICER of genotyping with ticagrelor is measured relative
to clopidogrel, and the ICER for ticagrelor is measured relative to geno-
typing with ticagrelor. As the discrimination of the test is dialed up
(moving rightward on the x-axis), carriers have more thrombotic events
and fewer bleeding events relative to noncarriers. This results in im-
proved outcomes associated with genotyping, making genotyping with
ticagrelor more cost-effective and treating all patients with ticagrelor
independent of genotype less cost-effective. As a point of reference, the
rate ratio for cardiovascular death (carriers to noncarriers) was 35%
greater in the high-discrimination scenario than in the base case.
ICER  incremental cost-effectiveness ratio; QALY  quality-adjusted
life-year.
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Appendix Figure 2. Tradeoff between bleeding and thrombosis.
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In 2-way sensitivity analyses, we simultaneously varied the rate of cardiovascular death and fatal bleeding among patients receiving ticagrelor (relative to
patients receiving clopidogrel), holding constant the event rates among patients receiving prasugrel. In the low-discrimination scenario and at a
willingness-to-pay threshold of $50 000/quality-adjusted life-year, genotyping with ticagrelor was the most cost-effective strategy at baseline (dotted lines),
but relatively small improvements in the efficacy or safety of ticagrelor (e.g., 1.3% decrease in cardiovascular mortality rates) made treating all patients
with ticagrelor the most cost-effective option. In the high-discrimination scenario, genotyping with ticagrelor was robust to large changes in the efficacy
and safety of ticagrelor. CV  cardiovascular; HR  hazard ratio.
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Appendix Figure 3. Effect of population frequency of CYP2C19 loss-of-function polymorphisms.
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As the population frequency of CYP2C19 loss-of-function polymorphisms increases, treating all patients receiving a percutaneous coronary intervention
for acute coronary syndrome with ticagrelor (independent of genotyping) becomes more cost-effective. At a threshold of $50 000/QALY, ticagrelor is the
most cost-effective strategy when carriers constitute 52.7% or more of the population. ICER  incremental cost-effectiveness ratio; QALY  quality-
adjusted life-year.
18 February 2014 Annals of Internal Medicine Volume 160 • Number 4 www.annals.org
Downloaded from https://annals.org by UC Irvine Med Ctr user on 10/04/2019
